News
RDi completes two acquisitions to support growth
23 Oct 2023
LDC-backed RDi, the UK’s leading automated, data-led healthcare fulfilment specialist, has acquired diagnostic sample collection and transport packaging provider MedDX, and biological sample packaging provider Shuttlepac. Both acquisitions have significantly broadened RDi’s portfolio of healthcare kitting and component capabilities, enabling it to better serve the evolving needs of its customers. The acquisitions have also created greater visibility and control over RDi’s supply chain and attracted a broader portfolio of customers.
RDi has grown 15% quarter on quarter in 2023 and is now setting its sights on expansion in the US market, the largest market in the world for home-testing kits. It plans to set up a manufacturing presence there in the next 12-18 months to meet the needs of large pharmaceutical companies.
Headquartered in Croydon, RDi provides data-led automation of fulfilment services for complex, customised and compliant kitting for the pharma services sector, solving complex logistical and technological challenges for patient sample collection. The business supports a broad range of sectors including large healthcare organisations to operate pioneering home testing kit programmes to support home testing and screening programmes such as bowel cancer and general wellness.
LDC invested in RDi in 2021 to support the management team’s organic growth. Since then, the business has expanded significantly, with headcount rising from 82 to 130, revenues increasing from £18m to £25m, and healthcare as a proportion of core business shifting from 22% to over 70%. The business has also made several senior appointments, including Sandra Evans, Global Sales Director, in May; Anthony Celli, Chief Commercial Officer, in July; and Gavin Cousins, Production Director, in September, to bolster the senior leadership team.
LDC backed our business in 2021, and supported us when it came to the acquisitions of MedDX and Shuttlepac. Looking ahead, we are really excited about the opportunity in the US, where a number of major pharmaceutical companies are interested in using our automation capability.”
Christian Bruning, Partner, LDC, added, “RDi has a unique proposition and is well positioned to take advantage of the phenomenal interest in healthcare screening, testing and monitoring, both in the US and globally. RDi has made its name with screening kits, including bowel cancer detection kits, since 2008, and is now successfully expanding this to other types of health screening as early-detection continues to rise up the agenda of individuals, companies and governments.”
“The business is also highly focused on sustainability, and on reducing the use of plastics by minimizing the size of its kits, components and packaging. We are proud to support RDi’s ambitious management team in their impressive growth story.”